# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k072409   
B. Purpose for Submission: Clearance of new device   
C. Measurand: Albumin Creatinine   
D. Type of Test: Albumin – Quantitative immunochemical assay Creatinine – Quantitative enzymatic assay   
E. Applicant: AXIS-SHIELD POC AS   
F. Proprietary and Established Names: Afinion™ ACR and Afinion™ ACR Control

G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>ProductCode</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=2 colspan=1>JIR</td><td rowspan=1 colspan=1>Class I subject</td><td rowspan=2 colspan=1>862.1645 - Urinary protein or albumin(nonquantitative) test system.</td><td rowspan=2 colspan=1>75</td></tr><tr><td rowspan=1 colspan=1>to 862.9 (c)(5)</td></tr><tr><td rowspan=1 colspan=1>JFY</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>862.1225 Creatinine test system.</td><td rowspan=1 colspan=1>75</td></tr><tr><td rowspan=2 colspan=1>JJY</td><td rowspan=2 colspan=1>Class Ireserved</td><td rowspan=1 colspan=1>862.1660 Quality control material (assayed and</td><td rowspan=2 colspan=1>75</td></tr><tr><td rowspan=1 colspan=1>unassayed).</td></tr></table>

# H. Intended Use:

1. Intended use(s):

Afinion™ ACR is an in vitro diagnostic test for quantitative determination of albumin, creatinine and albumin/creatinine ratio (ACR) in human urine. The measurement of urine albumin, creatinine and albumin/creatinine ratio aids in the early diagnosis of nephropathy.

Afinion™ ACR Control is a assayed in vitro diagnostic quality control material used to confirm that the Afinion™ ACR and the Afinion™ AS100 Analyzer System is working properly and provides reliable results.

2. Indication(s) for use:

Afinion™ ACR is an in vitro diagnostic test for quantitative determination of albumin, creatinine and albumin/creatinine ratio (ACR) in human urine. The measure of urine albumin aids in the early diagnosis of nephropathy.

Afinion™ ACR Control is a assayed in vitro diagnostic quality control material used to confirm that the Afinion™ ACR and the Afinion™ AS100 Analyzer System is working properly and provides reliable results.

3. Special conditions for use statement(s): For prescription use only

4. Special instrument requirements: Afinion™ ACR is used with the Afinion™ AS100 Analyzer

# I. Device Description:

The main components of the Afinion™ ACR Test Cartridge are the sampling device and the reaction container. The Test Cartridge has a handle, a barcode label with lot specific information and an area for sample ID.

Material provided:15 Afinion™ ACR Test Cartridges packaged separately in foil pouches with a desiccant bag, 1 Package Insert

The Afinion™ ACR Control kit contains liquid preparations of albumin and creatinine in citrate buffer. The Afinion™ ACR Controls have been designed for use with the Afinion™ AS100 Analyzer and the Afinion™ ACR test.

Control kit contents: 1 Afinion™ ACR Control C I: Citrate buffer with albumin and creatinine $\mathbf { \tau } ^ { \mathrm { ( 1 x 1 . 0 ~ m L ) } }$ ), 1 Afinion™ ACR Control C II: Citrate buffer with albumin and creatinine $\left( 1 \mathrm { x } 1 . 0 \mathrm { m L } \right)$ ), 1 Package Insert

# J. Substantial Equivalence Information:

DCA 2000Â® Microalbumin/Creatinine Assay k963142   

<table><tr><td colspan="1" rowspan="1">Predicate</td><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Similarities</td><td colspan="1" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">K963142 - DCA2000AMicroalbumin/CreatininemeasuredAssay</td><td colspan="1" rowspan="1">Analytes</td><td colspan="1" rowspan="1">Albumin, creatinine and ACR</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1">K963142 - DCA2000Microalbumin/CreatinineuseAssay</td><td colspan="1" rowspan="1">Intended</td><td colspan="1" rowspan="1">In vitro diagnostic test forquantitative determination ofalbumin, creatinine and ACR</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1">K963142 - DCA0R 0AMicroalbumin/CreatininematerialAssay</td><td colspan="1" rowspan="1">Sample</td><td colspan="1" rowspan="1">Human urine</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1">K963142 - DCA2000AMicroalbumin/CreatininetestAssay</td><td colspan="1" rowspan="1">Type of</td><td colspan="1" rowspan="1">Point of Care testing</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1">K963142 - DCA00AMicroalbumin/CreatinineAssay</td><td colspan="1" rowspan="1">Assayprnciplef for albumin</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">Afinion™ ACR: Immunometricmembrane flow-throughprinciple where the colorintensity of the membrane ismeasured by reflection.DCA® 2000Microalbumin/Creatinine assay:A specific antibody binds withalbumin in the presence ofpolyethylene glycol. Thealbumin antibody complexes aremeasured as absorbance.</td></tr><tr><td colspan="1" rowspan="1">K963142 - DCA2000AMicroalbumin/CreatinineAssay</td><td colspan="1" rowspan="1">Assayprincipleforcreatinine</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">Afinion™M ACR: An enzymaticcolorimetric test where thecreatinine concentration ismeasured by transmission.DCA® 2000Microalbumin/Creatinine assay:Benedict/Behre chemistry (nonenzymatic) and the creatinineconcentration is quantified byabsorbance.</td></tr><tr><td colspan="1" rowspan="1">K963142 - DCA00AMicroalbumin/CreatinineAssay</td><td colspan="1" rowspan="1">Measuringrangealbumin</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">Afinion™M ACR: Albumin 5.0-200 mg/LDCA® 2000Microalbumin/Creatinine assay:5.0-300.0 mg/L</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">K963142 - DCA2000AMicroalbumin/CreatinineAssay</td><td colspan="1" rowspan="1">Measuringrrangecreatinine</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">Afinion™M ACR: 16.4-339.9g/dLDCA® 2000Microalbumin/Creatinine assay:15-500 mg/dL</td></tr><tr><td colspan="1" rowspan="1">K963142 - DCA2000AMicroalbumin/CreatnineaACRAssay</td><td colspan="1" rowspan="1">Measuring</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">Afinion™M ACR: 1.0-1250.0mg/gDCA® 2000: 1-2000 mg/g</td></tr><tr><td colspan="1" rowspan="1">K963142 - DCA 20AMicroalbumin/Creatinine volumeAssay</td><td colspan="1" rowspan="1">Sample</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">AfinionTM ACR: 3.5 μLDCA® 2000Microalbumin/Creatinine assay:40 µ</td></tr><tr><td colspan="1" rowspan="1">K963142 - DCA2000AMicroalbumin/Creatinine carteAssay</td><td colspan="1" rowspan="1">Test</td><td colspan="1" rowspan="1">Ready to use</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1">K963142 - DCA2000AMicroalbumin/CreatinineAssay</td><td colspan="1" rowspan="1">Controlmaterial</td><td colspan="1" rowspan="1">2 control levels</td><td colspan="1" rowspan="1">Afinion™ ACR: ready to useDCA® 2000Microalbumin/Creatinine assay:lyophilized</td></tr><tr><td colspan="1" rowspan="1">K963142 - DCA2000AMicroalbumin/CreatininAssay</td><td colspan="1" rowspan="1">Storagetemperature for testcartridgesad controlmaterial</td><td colspan="1" rowspan="1">2-8</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1">K963142 - DCA2000AMicroalbumin/CreatinineAssay</td><td colspan="1" rowspan="1">Total precisionextnalstudy</td><td colspan="1" rowspan="1">AfinionTM ACR: albumin 3-8%CV, creatinine 3-8 %CV.DCA® 2000Microalbumin/Creatinine assay:albumin 2.7-6.6 %CV, creatinine2.8-3.6 %CV</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1">K963142 - DCA2000AMicroalbumin/CreatinineAssay</td><td colspan="1" rowspan="1">Assay time</td><td colspan="1" rowspan="1">N/A</td><td colspan="1" rowspan="1">Afinion™ ACR: 5 min 35 secDCA® 2000Microalbumin/Creatinine assay:7 minutes</td></tr><tr><td colspan="1" rowspan="1">K963142 - DCA2000AMicroalbumin/CreatinineAssay</td><td colspan="1" rowspan="1">CalibrationN/A</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Afinion™ ACR: Built inDCA 2000Microalbumin/Creatinine assay:Calibration card for test andcontrols</td></tr><tr><td>K963142 - DCA 2000A®</td><td></td><td></td><td>Afinion™M ACR: 15 tests</td></tr><tr><td>Microalbumin/Creatinine Assay</td><td>Kit size</td><td>Separately packed cartridges</td><td>DCA® 2000 Microalbumin/Creatinine assay: 10 tests</td></tr></table>

K. Standard/Guidance Document Referenced (if applicable):   

<table><tr><td>STANDARDS</td></tr><tr><td>Title and Reference Number</td></tr><tr><td>Stability Testing of In Vitro Diagnostic Reagents (CEN-13640)</td></tr><tr><td>Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline-Second Edition (EP5-A2)</td></tr></table>

# L. Test Principle:

Afinion™ ACR is a fully automated assay for determination of albumin, creatinine and ACR in human urine. Albumin is quantified using a solid phase immunochemical assay. In the Afinion™ ACR Test Cartridge the sample is automatically diluted and aspirated through a membrane coated with anti-albumin antibodies, which concentrates and immobilizes the albumin from the sample. A gold-antibody conjugate then binds to the immobilized albumin resulting in a redbrown colored membrane. Excess gold-antibody conjugate is removed in a washing step. The Afinion™ AS100 Analyzer measures the color intensity of the membrane, which is proportional to the amount of albumin in the sample.

Creatinine is quantified using an enzymatic colorimetric test that involves four enzymatic steps. The test requires incubation with two distinct enzyme solutions. A colored end product is measured in one of the cartridge wells.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

A 20 day study was performed with the Afinion™ ACR assay using the Afinion™ AS100 Analyzer to estimate the within-day, within-run, betweenday and total precision according to Clinical and Laboratory Standards Institute (CLSI) guideline EP5-A2.

Within-day precision was run with 20 replicates in one day. For within-run, between day and total precision, the testing was performed over 20 operating days. Each sample was measured in duplicate in two daily runs with a minimum of two hours between the two runs. Three urine samples were

collected and stored frozen until use. No samples were spiked. The samples were analyzed in random order for each run.

Within day imprecision results (20 replicates in 1 day) for albumin, creatinine and ACR.

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=2>S 1</td><td rowspan=1 colspan=2>S 2</td><td rowspan=1 colspan=2>S 3</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>mean</td><td rowspan=1 colspan=1>CV %</td><td rowspan=1 colspan=1>mean</td><td rowspan=1 colspan=1>CV %</td><td rowspan=1 colspan=1>mean</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>Albumin, mg/L</td><td rowspan=1 colspan=1>176.7</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>55.7</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>13.0</td><td rowspan=1 colspan=1>3.5</td></tr><tr><td rowspan=1 colspan=1>Creatinine, mg/dL</td><td rowspan=1 colspan=1>52.7</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>163.7</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>351.4</td><td rowspan=1 colspan=1>3.3</td></tr><tr><td rowspan=1 colspan=1>ACR, mg/g</td><td rowspan=1 colspan=1>335.8</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>34.1</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>4.0</td></tr></table>

Within run imprecision results for albumin, creatinine and ACR, 20 days testing of 3 urine samples.

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=2>S 1</td><td rowspan=1 colspan=2>S 2</td><td rowspan=1 colspan=2>S 3</td></tr><tr><td rowspan=1 colspan=1>Within run</td><td rowspan=1 colspan=1>mean</td><td rowspan=1 colspan=1>CV %</td><td rowspan=1 colspan=1>mean</td><td rowspan=1 colspan=1>CV %</td><td rowspan=1 colspan=1>mean</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>Albumin, mg/L</td><td rowspan=1 colspan=1>174.9</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>55.3</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>12.6</td><td rowspan=1 colspan=1>4.4</td></tr><tr><td rowspan=1 colspan=1>Creatinine, mg/dL</td><td rowspan=1 colspan=1>51.4</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>162.3</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>348.1</td><td rowspan=1 colspan=1>2.7</td></tr><tr><td rowspan=1 colspan=1>ACR, mg/g</td><td rowspan=1 colspan=1>340.6</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>34.1</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>5.0</td></tr></table>

Between day imprecision results for Albumin, Creatinine and ACR values after 20 days testing of 3 urine samples.

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=2>S 1</td><td rowspan=1 colspan=2>S 2</td><td rowspan=1 colspan=2>S 3</td></tr><tr><td rowspan=1 colspan=1>Between day</td><td rowspan=1 colspan=1>mean</td><td rowspan=1 colspan=1>CV %</td><td rowspan=1 colspan=1>mean</td><td rowspan=1 colspan=1>CV %</td><td rowspan=1 colspan=1>mean</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>Albumin, mg/L</td><td rowspan=1 colspan=1>174.9</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>55.3</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>12.6</td><td rowspan=1 colspan=1>1.2</td></tr><tr><td rowspan=1 colspan=1>Creatinine, mg/dL</td><td rowspan=1 colspan=1>51.4</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>162.3</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>348.1</td><td rowspan=1 colspan=1>0.6</td></tr><tr><td rowspan=1 colspan=1>ACR, mg/g</td><td rowspan=1 colspan=1>340.6</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>34.1</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>0.0</td></tr></table>

Total imprecision of Albumin, Creatinine and ACR values after 20 days testing of 3 urine samples.

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=2>S 1</td><td rowspan=1 colspan=2>S 2</td><td rowspan=1 colspan=2>S 3</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>mean</td><td rowspan=1 colspan=1>CV %</td><td rowspan=1 colspan=1>mean</td><td rowspan=1 colspan=1>CV %</td><td rowspan=1 colspan=1>mean</td><td rowspan=1 colspan=1>CV %</td></tr><tr><td rowspan=1 colspan=1>Albumin, mg/L</td><td rowspan=1 colspan=1>174.9</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>55.3</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>12.6</td><td rowspan=1 colspan=1>5.5</td></tr><tr><td rowspan=1 colspan=1>Creatinine, mg/dL</td><td rowspan=1 colspan=1>51.4</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>162.3</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>348.1</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=1 colspan=1>ACR, mg/g</td><td rowspan=1 colspan=1>340.6</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>34.1</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>6.0</td></tr></table>

Afinion™ ACR reportable range is supported by linearity and detection limit below:   

<table><tr><td>Albumin</td><td></td><td>Creatinine</td><td>ACR</td></tr><tr><td>Reportable range</td><td>5.0-200.0 mg/L</td><td>16.4-339.9 mg/dL</td><td>1.0-1250.0 mg/g</td></tr></table>

If the patient’s albumin or creatinine value is outside the reportable range, no ACR test result will be reported

# Procedure:

Two dilution series, one for albumin, AL1-AL10 and one for creatinine, CL1- CL10, were prepared by inter-mixing the high and low concentration of albumin and creatinine in urine samples as described in the table below:

<table><tr><td rowspan=1 colspan=1>Sample name</td><td rowspan=1 colspan=1>Sample Low(μL)= V1</td><td rowspan=1 colspan=1>Sample High(μL)= V2</td></tr><tr><td rowspan=1 colspan=1>AL1orCL1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>300</td></tr><tr><td rowspan=1 colspan=1>AL2orCL2</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>240</td></tr><tr><td rowspan=1 colspan=1>AL3orCL3</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>210</td></tr><tr><td rowspan=1 colspan=1>AL4orCL4</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>180</td></tr><tr><td rowspan=1 colspan=1>AL5orCL5</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>150</td></tr><tr><td rowspan=1 colspan=1>AL6orCL6</td><td rowspan=1 colspan=1>180</td><td rowspan=1 colspan=1>120</td></tr><tr><td rowspan=1 colspan=1>AL7orCL7</td><td rowspan=1 colspan=1>210</td><td rowspan=1 colspan=1>90</td></tr><tr><td rowspan=1 colspan=1>AL8orCL8</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>60</td></tr><tr><td rowspan=1 colspan=1>AL9orCL9</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>AL10 orCL110</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>0</td></tr></table>

The following linear regression results were obtained:   

<table><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>r^2}$</td><td rowspan=1 colspan=1>slope</td><td rowspan=1 colspan=1>y-intercept</td></tr><tr><td rowspan=1 colspan=1>Albumin</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>1.01 ± 0.02</td><td rowspan=1 colspan=1>-4.1 ± 1.9mg/L</td></tr><tr><td rowspan=1 colspan=1>Creatinine</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>0.99 ± 0.01</td><td rowspan=1 colspan=1>0.5 ± 2.1 mg/dL</td></tr></table>

Theoretical and measured albumin values.

<table><tr><td colspan="1" rowspan="1">Sample</td><td colspan="1" rowspan="1">Theoreticalalbumin (mg/L)</td><td colspan="1" rowspan="1">MeasuredMean albumin(mg/L)</td><td colspan="1" rowspan="1">CV %</td><td colspan="1" rowspan="1">% Recovery</td></tr><tr><td colspan="1" rowspan="1">AL1</td><td colspan="1" rowspan="1">201.8</td><td colspan="1" rowspan="1">201.8</td><td colspan="1" rowspan="1">5.3</td><td colspan="1" rowspan="1">N/A</td></tr><tr><td colspan="1" rowspan="1">AL2</td><td colspan="1" rowspan="1">162.2</td><td colspan="1" rowspan="1">159.0</td><td colspan="1" rowspan="1">3.9</td><td colspan="1" rowspan="1">98</td></tr><tr><td colspan="1" rowspan="1">AL3</td><td colspan="1" rowspan="1">142.5</td><td colspan="1" rowspan="1">148.4</td><td colspan="1" rowspan="1">3.0</td><td colspan="1" rowspan="1">104</td></tr><tr><td colspan="1" rowspan="1">AL4</td><td colspan="1" rowspan="1">122.7</td><td colspan="1" rowspan="1">124.3</td><td colspan="1" rowspan="1">4.0</td><td colspan="1" rowspan="1">101</td></tr><tr><td colspan="1" rowspan="1">AL5</td><td colspan="1" rowspan="1">102.9</td><td colspan="1" rowspan="1">106.8</td><td colspan="1" rowspan="1">4.7</td><td colspan="1" rowspan="1">104</td></tr><tr><td colspan="1" rowspan="1">AL6</td><td colspan="1" rowspan="1">83.1</td><td colspan="1" rowspan="1">89.7</td><td colspan="1" rowspan="1">4.6</td><td colspan="1" rowspan="1">108</td></tr><tr><td colspan="1" rowspan="1">AL7</td><td colspan="1" rowspan="1">63.3</td><td colspan="1" rowspan="1">67.3</td><td colspan="1" rowspan="1">4.6</td><td colspan="1" rowspan="1">106</td></tr><tr><td colspan="1" rowspan="1">AL8</td><td colspan="1" rowspan="1">43.6</td><td colspan="1" rowspan="1">48.3</td><td colspan="1" rowspan="1">2.7</td><td colspan="1" rowspan="1">111</td></tr><tr><td colspan="1" rowspan="1">AL9</td><td colspan="1" rowspan="1">23.8</td><td colspan="1" rowspan="1">27.5</td><td colspan="1" rowspan="1">4.4</td><td colspan="1" rowspan="1">116</td></tr><tr><td colspan="1" rowspan="1">AL10</td><td colspan="1" rowspan="1">4.0</td><td colspan="1" rowspan="1">4.0</td><td colspan="1" rowspan="1">4.3</td><td colspan="1" rowspan="1">N/A</td></tr></table>

Theoretical and measured creatinine values

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>MeasuredMean creatinine(mg/dL)</td><td rowspan=1 colspan=1>Theoreticalcreatinine(mg/dL)</td><td rowspan=1 colspan=1>CV %</td><td rowspan=1 colspan=1>% Recovery</td></tr><tr><td rowspan=1 colspan=1>CL1</td><td rowspan=1 colspan=1>343.7</td><td rowspan=1 colspan=1>343.7</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>CL2</td><td rowspan=1 colspan=1>275.3</td><td rowspan=1 colspan=1>277.2</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>99</td></tr><tr><td rowspan=1 colspan=1>CL3</td><td rowspan=1 colspan=1>250.8*</td><td rowspan=1 colspan=1>244.0</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>103</td></tr><tr><td rowspan=1 colspan=1>CL4</td><td rowspan=1 colspan=1>217.4</td><td rowspan=1 colspan=1>210.7</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>103</td></tr><tr><td rowspan=1 colspan=1>CL5</td><td rowspan=1 colspan=1>174.2</td><td rowspan=1 colspan=1>177.5</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>98</td></tr><tr><td rowspan=1 colspan=1>CL6</td><td rowspan=1 colspan=1>145.8</td><td rowspan=1 colspan=1>144.3</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>101</td></tr><tr><td rowspan=1 colspan=1>CL7</td><td rowspan=1 colspan=1>109.5</td><td rowspan=1 colspan=1>111.0</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>99</td></tr><tr><td rowspan=1 colspan=1>CL8</td><td rowspan=1 colspan=1>77.4</td><td rowspan=1 colspan=1>77.8</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>99</td></tr><tr><td rowspan=1 colspan=1>CL9</td><td rowspan=1 colspan=1>44.4</td><td rowspan=1 colspan=1>44.5</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>CL10</td><td rowspan=1 colspan=1>11.3</td><td rowspan=1 colspan=1>11.3</td><td rowspan=1 colspan=1>8.2</td><td rowspan=1 colspan=1>N/A</td></tr></table>

The albumin and creatinine assays show acceptable linearity over the measuring ranges.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Test specific calibration data are established for each lot of test cartridges and then stored in the barcode label. When the Test Cartridge enters the Analyzer, the integrated camera reads the barcode. The calibration data for the actual lot are transferred to the instrument and used for calculating results. Calibration by the operator is thus not required.

The albumin standards are traceable to ERM $^ \mathrm { \textregistered }$ -DA 470 and the creatinine standards are traceable to SRM 914a. Controls and calibrators are prepared gravimetrically. Values are assigned using analysis of multiple replicates on multiple analyzers and multiple lots.

Afinion™ ACR Control C I and C II were used when performing the external precision study for Afinion™ ACR Control. The controls C I and C II represent two different levels of albumin and creatinine according to table below and contains liquid preparations of albumin and creatinine in citrate buffer.

Target values for Afinion™ ACR Control C I and C II are assigned within the following ranges.

<table><tr><td rowspan=1 colspan=1>Specification</td><td rowspan=1 colspan=1>Target valueAlbumin(mg/L)</td><td rowspan=1 colspan=1>Target valueCreatinine(mg/dL)</td><td rowspan=1 colspan=1>Target valueACR(mg/g)</td></tr><tr><td rowspan=1 colspan=1>AfinionT ACRControl C I</td><td rowspan=1 colspan=1>9-15</td><td rowspan=1 colspan=1>79.2-101.8</td><td rowspan=1 colspan=1>8.8-18.9</td></tr><tr><td rowspan=1 colspan=1>AfinionTACRControl C II</td><td rowspan=1 colspan=1>65-95</td><td rowspan=1 colspan=1>203.6-248.8</td><td rowspan=1 colspan=1>26.1-46.7</td></tr></table>

Stability studies are conducted to determine the stability of Afinion™ ACR Control at the following conditions:

1. Real time storage at $5 \pm 3 ~ ^ { \circ } \mathrm { C }$ .

2. Open bottle at recommended storage at $5 \pm 3 ~ ^ { \circ } \mathrm { C }$ .

3. Continuous open bottle at room temperature.

4. Controlled room temperature storage..

5. Transport simulation (Warehouse/Shipping, W/S) of kits stressed at 37 $\pm 2 ~ ^ { \circ } \mathrm { C }$ for 3 days followed by storage at $5 \pm 3 ~ ^ { \circ } \mathrm { C }$ .

6. Transport simulation (Freeze/Thaw, F/T) of kits stressed for 3 freeze/thaw cycles followed by storage at $5 \pm 3 ~ ^ { \circ } \mathrm { C }$ .

Study protocols and acceptance criteria were described and found to be acceptable.

# d. Detection limit:

The applicant determined the Limits of Detection (LoD) and the Limits of Quantitation (LoQ) for Albumin and Creatinine in the ACR assay according to CLSI protocol EP17-A.

The LoD is $0 . 5 \mathrm { m g / L }$ for Albumin and $1 . 9 \mathrm { m g / d L }$ for Creatinine The LoQ is $2 . 5 \mathrm { m g / L }$ for Albumin and $5 . 0 \mathrm { m g / d L }$ for Creatinine

# e. Analytical specificity:

No cross-reaction was found when the albumin monoclonal antibodies were tested on human hemoglobin, IgG, IgA, beta-2 microglobulin, myoglobin and bovine serum albumin. (Note: See below. Interference from blood was observed with this device)

Interference

No significant interference was observed for both albumin and creatinine up to the following concentrations in urine:

Acetoacetate 0.84 mg/mL 7.8 mmol/L Acetone 800 mg/L 13.8 mmol/L Ascorbic acid 3000 mg/L 16.7 mmol/L Bilirubin 3.5 mg/dL 0.06 mmol/L Creatine 0.52 mg/mL 4.0 mmol/L Glucose 45 mg/mL 250 mmol/L beta-hydroxybutyric acid 5.9 mg/mL 46.8 mmol/L IgG 20 mg/L Beta-2 microglobulin 20 mg/L Myoglobin 20 mg/L Urea $3 0 \mathrm { m g / m L }$ 500 mmol/L

Over the counter and prescription drugs:

Acetaminophen 0.2 mg/mL 1.5 mmol/L Acetaminophen-glucuronide 10.5 mg/mL 30.0 mmol/L Glyburide 14.8 µg/mL 30 µmol/L Ibuprofen 2.0 mg/mL 10 mmol/L Metformin 4.0 mg/mL 24 mmol/L

Blood interference

Interference from blood may falsely elevate assay results when urine stick results are greater than or equal to 25 erythrocytes/uL.

No “Hook effect” was observed at albumin concentrations up to $5 0 0 0 \mathrm { m g / L }$ .

f. Assay cut-off: Not Applicable

a. Method comparison with predicate device:

External study

A method comparison study, comprising 169 urine samples was performed at four physicians’ office laboratories. Analyte concentrations were evenly distributed with albumin ranging from 5.0 to $2 0 0 . 0 \mathrm { m g / d L }$ and for creatinine from 17.0 and 339.4. Urine samples were collected from the donors and analyzed with Afinion™ ACR and another point-of-care method at the four study sites. The operators were either nurses or medical assistants.

The correlation data (Passing-Bablok analysis) are summarized below from the method comparison study - Afinion™ ACR (y) vs. another point-of care method (x) at four sites. (Linear regression analysis data, $\Nu =$ number of samples, $\mathbf { r } { = }$ correlation coefficient).

<table><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Regression line</td><td rowspan=1 colspan=1>r</td></tr><tr><td rowspan=1 colspan=1>Albumin</td><td rowspan=1 colspan=1>169</td><td rowspan=1 colspan=1>Y=1.10x + 1.4</td><td rowspan=1 colspan=1>0.99</td></tr><tr><td rowspan=1 colspan=1>Creatinine</td><td rowspan=1 colspan=1>169</td><td rowspan=1 colspan=1>Y=0.93x + 2.3</td><td rowspan=1 colspan=1>0.99</td></tr><tr><td rowspan=1 colspan=1>ACR</td><td rowspan=1 colspan=1>169</td><td rowspan=1 colspan=1>Y=1.16x + 1.0</td><td rowspan=1 colspan=1>0.99</td></tr></table>

Internal study performed at Axis shield PoC

Similarly another method comparison study comprised of 95 urine samples, with concentrations evenly distributed for albumin ranging from 5.0 to 199.6 $\mathrm { m g / d L }$ and creatinine from 17.4 and 332.2. were analyzed with Afinion™ ACR and another point-of-care method. The correlation data (Passing-Bablok analysis) are summarized here.

<table><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Regression line</td><td rowspan=1 colspan=1>r</td></tr><tr><td rowspan=1 colspan=1>Albumin</td><td rowspan=1 colspan=1>91</td><td rowspan=1 colspan=1>Y=0.92x + 2.1</td><td rowspan=1 colspan=1>0.99</td></tr><tr><td rowspan=1 colspan=1>Creatinine</td><td rowspan=1 colspan=1>95</td><td rowspan=1 colspan=1>Y=1.00x - 3.2</td><td rowspan=1 colspan=1>0.99</td></tr><tr><td rowspan=1 colspan=1>ACR</td><td rowspan=1 colspan=1>91</td><td rowspan=1 colspan=1>Y=1.01x + 0.7</td><td rowspan=1 colspan=1>0.99</td></tr></table>

b. Matrix comparison: Not Applicable

3. Clinical studies:

a. Clinical Sensitivity: Not Applicable

b. Clinical specificity: Not Applicable   
c. Other clinical supportive data (when a. and b. are not applicable): Not Applicable

4. Clinical cut-off: Not Applicable

5. Expected values/Reference range:

Reportable range of the Afinion™ ACR assay for Albumin: $5 . 0 { - } 2 0 0 \mathrm { m g / L }$ .

Albumin values and medical decision points:

\* Normal: $< 2 0 \mathrm { m g / L }$ \* Microalbuminuria: $2 0 { - } 2 0 0 \ \mathrm { m g / L }$ \* Clinical albuminuria: $> 2 0 0 \mathrm { m g / L }$

Ref: Janssen, W. M. T et al. Clin Chem Lab Med; 38 (11): 1107-1110; 2000.   
Torffvit, O. Diabetolognytt; No 1-2; 2002.

Reportable range of the Afinion™ ACR assay for Creatinine is 16.4-339.9 mg/dL

The normal range for urine creatinine: 34-147 mg/dL

Ref: Foss OP. Fysiologi Patofysiologi Klinsk Kjem. Noen momenter for fysiokjemikere, $\mathrm { \dot { 2 } ^ { n d } }$ ed.Ulleval sykehus, Oslo, 1981; 99/

Reportable range of the Afinion™ ACR assay for Albumin Creatinine Ratio $( \mathrm { A C R } ) \colon 1 . 0 { - } 1 2 5 0 \ \mathrm { m g / g }$ .

ACR values and medical decision points:

\* Normal: $< 3 0 \mathrm { m g / g }$ \* Microalbuminuria: $3 0 { - } 3 0 0 \mathrm { m g / g }$ \* Clinical albuminuria: $> 3 0 0 \mathrm { m g / g }$

Ref: American Diabetes Association. Diabetes care, Vol. 25, Suppl.1, January 2002.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.